Salemonline Journal

Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032

 Breaking News
  • No posts were found

Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032

September 20
04:16 2022
Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032
Dermatomyositis Market
As per DelveInsight’s assessment, the Dermatomyositis Market is expected to grow in the coming years owing to the rising incidence, growing disease awareness, and the launch of promising therapies by key players such as Corbus Pharmaceuticals, CSL Behring, Provant Therapeutics, and others.

DelveInsight’s Dermatomyositis Market Insights Report provides a comprehensive understanding of current treatment practices, emerging drugs, Dermatomyositis market share of individual therapies, and current and forecasted Dermatomyositis market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Highlights from the Dermatomyositis Market Report

  •  Dermatomyositis is more common in women than in men, with incidence rates being 3.98 and 4.68 per 1,000,000, respectively.
  • Dermatomyositis is estimated to be around 9.63 cases per million people globally. In children, dermatomyositis symptoms commonly occur between 5 and 15 years of age.

Dermatomyositis Overview

Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes in the muscles. Muscle aches, weakness, abnormality, and weakness are being observed. It may lead to a reddish-purple rash on the upper eyelids or cheeks. Symptoms include difficulty in raising the arms. There is no specific cause, for it might be due to environmental, genetic, or immunological factors.

Dermatomyositis Treatment Market 

The first-line treatment of Dermatomyositis includes systemic glucocorticoids with or without immunosuppressants.  A high dose of  Prednisolone is given at the beginning to improve muscle strength. 

Rituximab, mycophenolate, mofetil, calcineurin, and intravenous inhibitors are given to patients who do not respond positively to the first-line treatment. Second Line Therapy- involves a combination of azathioprine and methotrexate 

Dermatomyositis disease is also managed by general measures, physiotherapy, and medical therapy. Avoid sunlight and sun-protective clothing. Physical therapy and rehabilitation play an important role. Patients are encouraged to participate actively in exercise programs.

Learn more about the treatment options @ Dermatomyositis Treatment Market

Dermatomyositis Epidemiology Segmentation

The Dermatomyositis market report offers epidemiological analysis for the study period 2019-32 in the 7MM segmented into

  •  Dermatomyositis Total Incident Cases 
  •  Dermatomyositis Gender-specific Incident Cases 
  •  Dermatomyositis Subtype-specific Incident Cases 
  •  Dermatomyositis Severity-specific Incident Cases 
  •  Dermatomyositis Treatable Cases 

Download the report to understand which factors are guiding epidemiology trends @ Dermatomyositis Epidemiological Insights

Scope of the Dermatomyositis Market Report

  • Study Period: 2019-32
  • Coverage: TheUnitedStates, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
  • Therapeutic Assessment: Dermatomyositis off-label and emerging therapies
  • Key Dermatomyositis Companies: Private, Corbus Pharmaceuticals, CSL Behring, and many others.
  • Market Dynamics: Dermatomyositis market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

Table of Contents

1.

Dermatomyositis Market Key Insights

2.

Dermatomyositis  Market Report Introduction

3.

Dermatomyositis  Market Overview at a Glance

4.

Dermatomyositis  Market Executive Summary

5.

Disease Background and Overview

6.

Dermatomyositis Treatment and Management

7.

Dermatomyositis  Epidemiology and Patient Population

8.

Patient Journey

10.

Dermatomyositis  Emerging Drugs

12.

Dermatomyositis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Dermatomyositis   Market Drivers

16.

Dermatomyositis   Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles